Boaz is a serial entrepreneur and one of the trailblazers in the field of high-tech in Israel. His notable contributions include co-founding several successful companies, including Comverse, Verint Systems, Telemesser, DSP, Fundtech, Versamed, and others. These ventures not only achieved remarkable success but also paved the way for the establishment of numerous other technology ventures throughout Israel. Boaz’s entrepreneurial spirit and visionary leadership have made a lasting impact on the Israeli high-tech landscape.

Haim Cohen, a professor at Bar-Ilan University, is an internationally recognized expert in the field of aging and a prominent figure in SIRT6 research. He serves as the Head of the Israeli-German Minerva Center for Biological Mechanisms of Healthy Aging, the National Excellence Center for Metabolic Research, and the Sagol Healthy Longevity Center at Bar-Ilan University. With his extensive knowledge and leadership, Professor Cohen plays a pivotal role in advancing our understanding of healthy aging and the significant implications of SIRT6 in age-related processes. 

Amir has a wealth of experience in the realm of finance, encompassing expertise in financing, mezzanine loans, merger, and acquisition transactions. He has successfully invested in over 18 private ventures and has served as the CEO of a private equity fund. Amir brings a valuable perspective and strategic insight to the table.

Hagit brings 20 years of professional experience, during which she has consistently demonstrated progressive expertise in leadership and successfully managed multiple R&D projects concurrently. Her extensive knowledge and experience in drug development cover various product types, including RNA, small molecules, and antibodies, across numerous medical indications. Hagit was the VP of Research and Operation at Quark Pharmaceuticals for 12 years and served as a consultant for various drug development companies.

Renowned for his significant contributions in advancing the understanding of aging and promoting research in the field, Prof. Nir Barzilai holds the positions of Director of the Institute for Aging Research at the Albert Einstein College of Medicine, Director of the Paul F. Glenn center for the Biology of Human Aging Research, and Director of the National Institutes of Health’s (NIH) Nathan Shock centers of Excellence in the Basic Biology of Aging. Additionally, Prof. Barzilai serves as the Scientific Director of the American Federation for Aging Research (AFAR).

Prof. Dan Peer serves as the VP of R&D and the director of the Laboratory of Precision Nanomedicines at Tel Aviv University.  Prof. Peer’s groundbreaking technology has been licensed by several companies, including BioNTech / Pfizer. His pioneering work in the field was among the first to demonstrate the systemic delivery of RNA molecules using targeted nanocarriers to the immune system, showcasing his innovation and impact in advancing the field of nanomedicine.

Dr.  Michael G. Kauffman is a Board Member, Drug Developer, Entrepreneur, and Physician Scientist. He co-founded Karyopharm Therapeutics, Inc. and served as its CEO, making significant contributions to its success. Additionally, Dr. Kauffman held prominent positions such as CMO at Onyx Pharmaceuticals, Inc. and Proteolix, Inc., as well as President and CEO of Epix Pharmaceuticals, Inc. and Predix Pharmaceuticals, Inc. He was involved in the development of four new clinical candidates. Prior to these roles, Dr. Kauffman served as VP, Clinical Development at Millennium Pharmaceuticals, Inc., where he played a pivotal role in the approval of Velcade® in 2003.